Cell line development (CLD) is a critical component of any biologic development. CLD will lead to a successful
journey across numerous stringent regulatory approval processes and first-to-market of your innovative biologic molecule. The CLD process involves expert scientific personnel, various robust host cell lines, and advanced process development infrastructure to mitigate clinical trial failures and delivery of biotherapeutics to the critical patient population. In this article, we describe how collaborating with Aragen, your company will develop a cost effective CLD project and expedite the BLA and IND filings on your innovative biotherapeutic.
Scientists and technical staff at Aragen, supported by well-equipped laboratories serve you in customizing cell line
selection for developing research cell banks (RCBs). Our CLD expertise spans over 28 years in the industry, and our researchers are specialized in managing a wide range of host cell lines (CHO, SP2/0, and NS0) and expression vectors (DHFR, Glutamine Synthetase (GS), and antibiotics). We are also expert in developing new biologics that are difficult to express for a variety of reasons, including specific physicochemical features or complex formats. We have assisted our clients from molecule design to tech transfer to manufacturing. Continuous optimization of the CLD process
parameters based on the individual needs of the clients allowed us to improve with each new project.
As of today, Aragen has completed more than 200 CLD projects, with over one hundred of those cell lines in the clinic.
Presently, more than four of Aragen’s cell lines have produced marketed products. We oer several CLD platforms customized to the specific requirements of the customers. Currently, we offer three CHO CLD platforms namely CHO DG44, Sigma CHOZN GS, and Asimov CHO GS. Our internal CHO DG44 platform is a free-to-own (royalty-free) and high productivity option that can deliver >4g/L product in 5 months for a range of biologics: